Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

American Journal of Respiratory and Critical Care Medicine

Volumn 153, Issue 5, 1996, Pages 1481-1488

  Woolcock, Ann ^b   Lundback, Bo ^b   Ringdal, Nils ^b   Jacques, Loretta A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; SALBUTAMOL; SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREMOR;

EID: 0029880013     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.153.5.8630590     Document Type: Article

References (29)

1. 1992. International consensus report on the diagnosis and management of asthma. Clin. Exp. Allergy 22(Suppl.):1-72.
2. Guidelines on the Management of Asthma. 1993. Statement by the British Thoracic Society, the British Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the British Association of Accident and Emergency Medicine, and the British Paediatric Respiratory Group following a meeting at the Royal College of Physicians, London, June 4 and 5, 1992. Thorax 48(Suppl.):S1-S24.
3. Pharmacological Treatment of Bronchial Asthma. 1993. Recommendations in Pharmacological Treatment of Bronchial Asthma II. Pub Medical Products Agency. Uppsala, Sweden. 173-186.
4. 2-agonist, terbutaline with an inhaled corticosteroid budesonide in newly detected asthma. N. Engl. J. Med. 325:388-392.
5. Bel, E. H., M. C. Timmers, J. Hermans, J. H. Dijkman, and P. J. Sterk. 1990. The long term effects of nedocromil sodium and beclomethasone dipropionateon bronchial responsiveness to methacholine in nonatopic asthma subjects. Am. Rev. Respir. Dis. 141:21-28.
6. Juniper, E. F., P. A. Kline, M. A. Vanzieleghem, E. H. Ramsdale, P. M. O'Byrne, and F. E. Hargreave. 1990. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airways hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Rev. Respir. Dis. 142:832-836.
7. Fabbri, L., P. S. Burge, L. Croonenborgh, F. Warlies, B. Weeke, A. Ciaccia, and C. Parker. 1993. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treatment for one year. Thorax 48:817-823.
8. 2-adrenoceptor agonist: a comparison with salbutamol in adult asthmatic patients. Thorax 43:674-678.
9. Dahl, R., J. S. Earnshaw, and J. B. D. Palmer. 1991. Salmeterol: a four week study of long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur. Respir. J. 4:1178-1184.
10. Britton, M. G., J. S. Earnshaw, and J. B. D. Palmer. 1992. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur. Respir. J. 5:1062-1067.
11. Pearlman, D. S., P. Chervinsky, C. LaForce, J. M. Seltzer, D. L. Southern, J. P. Kemp, R. J. Dockhorn, J. Grossman, R. F. Liddle, S. W. Yancey, D. Cocchetto, W. J. Alexander, and A. van As. 1992. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N. Engl. J. Med. 327:1420-1425.
12. Palmer, J. B. D., A. M. Stuart, G. L. Shepherd, and K. Viskum. 1992. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease - a 3 month comparison of the efficacy and safety of twice daily salmeterol (100 μg) with salmeterol (50 μg). Respir. Med. 86:409-417.
13. Greening, A. P., P. W. Ing, M. Northfield, and G. Shaw. 1994. Treatment of adult asthmatic patients symptomatic on low dose inhaled corticosteroids: a comparison of the addition of salmeterol to existing inhaled corticosteroid therapy, with increasing the dose of inhaled corticosteroids. Lancet 344:219-224.
14. Toogood, J. H., N. M. Lefcoe, D. S. M. Haines, B. Jennings, N. Errington, L. Baksh, and L. Chuang. 1977. A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J. Allergy Clin. Immunol. 59:298-308.
15. Johansson, S. A., and R. Dahl. 1988. A double-blind dose response study of budesonide by inhalation in patients with bronchial asthma. Allergy 43:173-178.
16. Gaddie, J., G. R. Petrie, I. W. Reid, C. Skinner, D. J. M. Sinclair, and R. N. V. Palmer. 1973. Aerosol beclomethasone dipropionate and budesonide in the management of asthma. Lancet 2:280-281.
17. Boe, J., L. Rosenhall, M. Alton, L. G. Carlsson, U. Carlsson, B. A. Hermansson, L. Hetta, J. Kivilog, B. W. Karlson, B. Lundback, J. E. Martinsson, K. Nemcek, and C. Nemcek. 1989. Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma. Allergy 44:349-355.
18. 2-agonists on lung function, airway responsiveness and symptoms in children with asthma. Am. Rev. Respir. Dis. 146:547-554.
19. Hummel, S., L. Lehtonen, and study group. 1992. Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma. Lancet 340:1483-1487.
20. Van-Essen-Zandvliet, E. E., M. D. Hughes, H. J. Waalkens, E. J. Duiverman, K. F. Kerrebijn, and the Dutch CNS LD study group. 1994. Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Eur. Respir. J. 7:63-68.
21. Kraan, J., G. H. Koëter, T. W. vd Mark, H. J. Sluiter, and K. de Vries. 1985. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with anti-asthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J. Allergy Clin. Immunol. 76:628-636.
22. Lundgren, R., M. Soderberg, P. Hostedt, and R. Sterling. 1988. Morphological studies of bronchial mucosal biopsies from asthmatics before and ten years of treatment with inhaled steroids. Eur. Respir. J. 1:883-889.
23. Sears, M. R., D. R. Taylor, C. G. Print, D. C. Lake, L. Qingqing, E. M. Flannery, D. M. Yates, M. K. Lucas, and G. P. Herbison. 1990. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336:1391-1396.
24. van Schayck, C. P., E. Dompeling, C. L. A. Van Herwaarden, H. Folgering, A. L. M. Verbeek, H. J. M. Van der Hoogen, and C. Van Weel. 1991. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. B.M.J. 303:1426-1431.
25. vanSchyck, C. P., and C. L. A. van Herwaarden. 1993. Do bronchodilators adversely affect the prognosis of bronchial hyperresponsiveness. Thorax 48:470-473.
26. Campos Gongora, H., A. F. Z. Wisniewski, and A. E. Tattersfield. 1991. A single dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. Am. Rev. Respir. Dis. 144:626-629.
27. Derom, E. Y., R. M. Pauwels, and M. E. F. Van der Staeten. 1992. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J. Allergy Clin. Immunol. 89: 811-815.
28. Simons, F. E. R., N. R. Soni, W. T. A. Watson, and A. B. Becker. 1992. Bronchodilator and bronchprotective effects of salmeterol in young patients with asthma. J. Allergy Clin. Immunol. 90:840-846.
29. 2-agonist salmeterol in mild to moderate asthmatic patients. Thorax 48:1121-1124.